https://hspsignal.com/index.ph....p/health-benefits-of
But, the capecitabine-RT group was more prone to require customizations within the RT schedule, including therapy breaks or cancelled fractions (44% vs. 17%; otherwise, 3.89; 95% CI, 1.12-13.52; P = .03). CONCLUSION Capecitabine-RT is apparently safe within the adjuvant remedy for cancer of the breast with comparable toxicity to RT alone. It could require more therapy alterations. Potential researches are essential to gauge the security and tolerability with this combo. BACK
Like
Comment
Share
